Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.80 |
| ▸ | SYK | P43405 | 2/20 | 0.80 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.80 |
| ▸ | FES | P07332 | 1/20 | 0.80 |
| ▸ | FER | P16591 | 1/20 | 0.80 |
| ▸ | FRK | P42685 | 1/20 | 0.80 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.80 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.80 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18115290 | 1.00 | TYK2 (0.80) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18115391 | 0.95 | TYK2 (0.85) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18115397 | 0.95 | TYK2 (0.85) | TYK2SYKIRAK4FESFER | |
| SCHEMBL20507064 | 0.91 | TYK2 (0.78) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18121508 | 0.91 | TYK2 (0.78) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18115440 | 0.91 | TYK2 (0.86) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18115435 | 0.91 | TYK2 (0.86) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18115263 | 0.91 | TYK2 (0.82) | TYK2SYKIRAK4FESFER | |
| SCHEMBL18115267 | 0.91 | TYK2 (0.82) | TYK2SYKIRAK4FESFER | |
| SCHEMBL428784 | 0.89 | TYK2 (0.82) | TYK2SYKIRAK4FESFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180271873-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-09-27 | — | — | US | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271873-A1 | METHODS FOR TREATING VIRAL INFECTIONS | HAVCR2, CCL11, EIF2AK2 | TYK2 3663/4885SYK 2919/4885IRAK4 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.